Nuo Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: 10-year revenue-ramp unlevered FCF DCF: ~$6.1M FY2026 revenue base (H1 2026 revenue of $3.07M annualized); revenue growth tapering from 80% (year 1) to 5% (year 10) as Aurix wound-care Medicare reimbursement and commercial adoption scale; FCF margin ramping from -30% to an 18% steady-state margin; 18% discount rate; 3% terminal growth; $1.30M net debt subtracted (only $449K cash vs $1.75M debt); 48.41M shares outstanding.

Reasoning: Nuo Therapeutics is a recently-commercial regenerative wound-care company growing revenue over 150% but with only $449K of cash and a going-concern note in its latest 10-Q, so a staged revenue/margin DCF with a high discount rate for execution and liquidity risk is more informative than valuing today's negative cash flow.